IonQ Unveils Its First Quantum Computer in Europe, Online Now at a Record #AQ36
5.12.2024 14:05:00 CET | Business Wire | Press release
IonQ’s quantum computer Forte Enterprise has achieved the record-breaking milestone of #AQ36In partnership with QuantumBasel, IonQ Forte Enterprise will provide European Enterprise Customers, Industries, government entities, and research institutes with local access to IonQ’s most powerful quantum systemsIonQ has opened its First European Innovation Center at the uptownBasel campus in Arlesheim, Switzerland
IonQ (NYSE: IONQ), a leader in the quantum computing and networking industry, today announced the delivery of IonQ Forte Enterprise to its first European Innovation Center at the uptownBasel campus in Arlesheim, Switzerland. Achieved in partnership with QuantumBasel, this major milestone marks the first datacenter-ready quantum computer IonQ has delivered that will operate outside the United States and the first quantum system for commercial use in Switzerland.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241205805000/en/

IonQ European Innovation Center - Arlesheim, Switzerland (Photo: Business Wire)
Forte Enterprise is now online servicing compute jobs while performing at a record algorithmic qubit count of #AQ36, which is significantly more powerful than the promised #AQ35. With each additional #AQ, the useful computational space for running quantum algorithms doubles. A system with #AQ36 is capable of considering more than 68 billion different possibilities simultaneously. With this milestone, IonQ once again leads the industry in delivering production-ready systems to customers.
“The successful commissioning of Forte Enterprise in Europe – on schedule and at an even higher performance level than announced previously – demonstrates IonQ’s commitment to driving global quantum adoption through technological leadership and operational excellence,” said Peter Chapman, CEO and President of IonQ. “Achieving #AQ36 is a significant leap forward, opening new possibilities for applications including logistics, finance, pharmaceuticals, chemistry and artificial intelligence.”
“Offering the state-of-the-art Forte Enterprise quantum computing platform to our ecosystem will accelerate the development of quantum applications across a range of fields,” said Damir Bogdan, CEO of QuantumBasel. “By collaborating with IonQ, we’re positioning the uptownBasel campus as a leader in quantum innovation, fostering breakthroughs that address real-world challenges.”
IonQ’s next generation commercial quantum systems such as Forte Enterprise are optimized for data center environments, sporting a rack-mounted form factor, low energy profile, and minimal environmental isolation requirements.
Building on a History of Excellence
Today’s IonQ Forte Enterprise system commissioning represents the culmination of IonQ’s engineering innovation, operational excellence, and enterprise-grade production capabilities.
“This milestone reflects the hard work and ingenuity of teams across IonQ and QuantumBasel,” said Dr. Dave Mehuys, VP of Production Engineering. “We aligned our system build with on-site datacenter construction and IonQ’s manufacturing and production teams leveraged their decades of expertise to bring this groundbreaking system online faster than anticipated.”
Pioneering a New Era of Computing
IonQ’s record-breaking achievement of #AQ36 signals the company’s dedication and success in advancing quantum performance. Forte Enterprise expands the potential for driving groundbreaking research in areas such as quantum chemistry and machine learning.
“IonQ’s ability to deliver Forte Enterprise with #AQ36 reflects our growing capabilities to execute on our mission to drive significant quantum advancements globally,” said Dr. Dean Kassmann, Senior Vice President of Engineering and Technology at IonQ. “Each step we take demonstrates our commitment to bringing quantum computing from the lab to practical, impactful, and commercial uses.”
A Quantum Leap for Europe and Beyond
IonQ’s first European Innovation Center will allow the company to service its European customers out of its QuantumBasel location and to drive research and development of next generation quantum applications in Europe.
As part of its partnership with IonQ, QuantumBasel will offer its ecosystem– including enterprises, research institutes, startups, and universities – direct access to the #AQ36 Forte Enterprise system.
With datacenters now in the Washington, D.C., Seattle, and Basel, Switzerland areas, IonQ has firmly established a global data center footprint, reinforcing its position as a leader in quantum technology.
To learn more about IonQ’s latest innovations, visit www.ionq.com.
About IonQ
IonQ, Inc. is a leader in quantum computing that delivers high-performance systems capable of solving the world’s largest and most complex commercial and research use cases. IonQ’s current generation quantum computer, IonQ Forte, is the latest in a line of cutting-edge systems, boasting 36 algorithmic qubits. The company’s innovative technology and rapid growth were recognized in Fast Company’s 2023 Next Big Things in Tech List and Deloitte’s 2023 Technology Fast 500™ List, respectively. Available through all major cloud providers, IonQ is making quantum computing more accessible and impactful than ever before. Learn more at IonQ.com.
About QuantumBasel
QuantumBasel is a competence center for quantum computing and AI and drives access to commercial quantum computing to foster innovation. QuantumBasel places particular emphasis on technological neutrality and is Switzerland’s first commercial quantum computing hub, providing access to hardware from IBM, D-Wave and IonQ. QuantumBasel’s team of quantum and data scientists trains and supports companies, conducts projects in quantum computing and AI, and collaborates closely with universities and academic institutions. Through an internationally connected ecosystem, QuantumBasel provides access to advanced know-how and technologies, enabling companies in industrial production, logistics, finance, energy, life sciences, and start-ups to achieve innovations they cannot develop independently. www.quantumbasel.com
IonQ Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the terms “adoption,” “advancing,” “advancements,” “collaborating,” “commitment,” “demonstrates,” “development,” “groundbreaking” “milestone,” “next generation,” “optimized,” “potential,” “significant leap forward,” “state-of-the-art,” “will,” and other similar expressions are intended to identify forward-looking statements. These statements include those related to the company’s technology driving commercial quantum advantage in the future, the timing of delivering to customers IonQ Forte Enterprise systems, the planned increase to the footprint of the uptownBasel campus in Arlesheim, Switzerland, the company’s ability to establish public-private partnerships, the ability for third parties to implement IonQ’s offerings to increase their quantum computing capabilities, access to IonQ’s quantum computers, the ability to test and execute quantum applications on IonQ’s quantum computers, the opportunity to test and optimize novel quantum-enhanced algorithms for computational challenges on IonQ’s quantum computers; the problems that can be solved by IonQ’s quantum computers, the advantages of IonQ's approach to the manufacturing of IonQ’s systems, IonQ’s quantum computing capabilities and plans, and the scalability and reliability of IonQ’s quantum computing offerings. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: changes in the competitive industries in which IonQ operates; the ability of IonQ to protect its intellectual property; changes in laws and regulations affecting IonQ’s business; IonQ’s ability to implement its business plans, technical roadmap, and other expectations, identify and realize partnerships and opportunities, and to engage new and existing customers; or market adoption of quantum computing solutions and IonQ’s products, services and solutions. You should carefully consider the foregoing factors and the other risks and uncertainties disclosed in the Company’s filings, including but not limited to those described in the “Risk Factors” section of IonQ’s most recent Quarterly Report on Form 10-Q and other documents filed by IonQ from time to time with the Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and IonQ assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. IonQ does not give any assurance that it will achieve its expectations. IonQ may or may not choose to practice or otherwise use the inventions described in the issued patents in the future.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241205805000/en/


Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom